Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Bismuth Subnitrate and Iodoform Paste Impregnated Gauze

Active Ingredient:
bismuth subnitrate, iodoform
Martindale Pharma, an Ethypharm Group Company See contact details
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 18 Feb 2015
1. Name of the medicinal product

Bismuth Subnitrate and Iodoform Paste Impregnated Gauze.

2. Qualitative and quantitative composition

A lemon yellow paste impregnated gauze with characteristic antiseptic odour.

The gauze is impregnated with a paste of composition.

Bismuth Subnitrate

BPC 1973

20% w/w.


BPC 1954

40% w/w.

Paraffin Liquid


40% w/w.

3. Pharmaceutical form

A paste impregnated gauze.

4. Clinical particulars
4.1 Therapeutic indications

a) Post ENT Surgical Procedures

As an antiseptic gauze used to prevent infection and thus assist healing following ENT procedures.

It is not recommended that the impregnated gauze be placed into open wounds.

b) Acute Epistaxis

To pack the nasal cavity in order to reduce/stop the flow of blood.

4.2 Posology and method of administration

a) In ENT surgical procedures

Sufficient impregnated gauzes should be packed into the cavity to protect the operation site from bacterial challenge. The gauze is left in place until the wound has healed or graft taken.

It is not recommended that the impregnated gauze be placed into open wounds.

b) Acute epistaxis

Sufficient impregnated gauze(s) is packed up in the nose to stop the blood flow. The gauze is removed the following day or when clinical judgement dictates.

4.3 Contraindications

Known hypersensitivity to Iodoform, iodine and bismuth.

4.4 Special warnings and precautions for use

Use with caution with patients suffering from hyperthyroidism.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Pregnancy and lactation

There is insufficient evidence of safety in pregnancy, as with all drugs it is not recommended the product is used in pregnancy.

4.7 Effects on ability to drive and use machines

Not applicable.

4.8 Undesirable effects

Hypersensitivity to iodine can result in an erythematous rash, which subsides on removal of the gauze.

Although rare, there are reports within the published literature of the development of encephalopathy associated with the application of BIPP, however none of the cases reported have occurred following ENT procedures.

4.9 Overdose

Severe iodine poisoning is characterised by headache, somnolence, delirium and rapid feeble pulses. General supportive procedures are required. Overdose is not usually a problem when gauzes are packed in small cavities associated with the middle ear and mastoid operations.

5. Pharmacological properties
5.1 Pharmacodynamic properties


Has a marked anaesthetic and antiseptic action due to the release of iodine.

Bismuth subnitrate:-

Bismuth subnitrate action is both as an astringent and absorbent.

5.2 Pharmacokinetic properties

Pharmacokinetic particulars are not applicable since the active constituents are not systemically absorbed.

5.3 Preclinical safety data

Not applicable

6. Pharmaceutical particulars
6.1 List of excipients

Paraffin Liquid BP

X-Ray detectable Fast Edge Ribbon Gauze

May also contain Purified water BP.

6.2 Incompatibilities

The paste is incompatible with oxidising agents - lead, silver and mercuric salt.

6.3 Shelf life

2 years

6.4 Special precautions for storage

Store between 2-8° C. Protect from light.

6.5 Nature and contents of container

An Aluminium laminated pouch of composition:


12 micron




9 micron



6.6 Special precautions for disposal and other handling

Discard any unused gauze at the end of a procedure or session. Do not use if the pouch is damaged.

7. Marketing authorisation holder

Aurum Pharmaceuticals Limited

Bampton Road

Harold Hill Romford

Essex RM3 8UG

8. Marketing authorisation number(s)

PL 12064/0002

9. Date of first authorisation/renewal of the authorisation

12th January 1995

10. Date of revision of the text

June 2002

Martindale Pharma, an Ethypharm Group Company
Company image
Jupiter House, Mercury Park, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0HH, UK
+44 (0) 1277 266 600
Medical Information e-mail
[email protected]